Biallelic variants in POPDC2 cause a novel autosomal recessive syndrome presenting with cardiac conduction defects and variable hypertrophic cardiomyopathy

ABSTRACT

POPDC2 encodes for the Popeye domain-containing protein 2 which has an important role in cardiac pacemaking and conduction, due in part to its cAMP-dependent binding and regulation of TREK-1 potassium channels. Loss of Popdc2 in mice results in sinus pauses and bradycardia and morpholino knockdown of popdc2 in zebrafish results in atrioventricular (AV) block. We identified bi-allelic variants in POPDC2 in 4 families that presented with a phenotypic spectrum consisting of sinus node dysfunction, AV conduction defects and hypertrophic cardiomyopathy. Using homology modelling we show that the identified POPDC2 variants are predicted to diminish the ability of POPDC2 to bind cAMP. In in vitro electrophysiological studies we demonstrated that, while co-expression of wild-type POPDC2 with TREK-1 increased TREK-1 current density, POPDC2 variants found in the patients failed to increase TREK-1 current density. While patient muscle biopsy did not show clear myopathic disease, it showed significant reduction of the expression of both POPDC1 and POPDC2, suggesting that stability and/or membrane trafficking of the POPDC1–POPDC2 complex is impaired by pathogenic variants in any of the two proteins. Single-cell RNA sequencing from human hearts demonstrated that co-expression of POPDC1 and 2 was most prevalent in AV node, AV node pacemaker and AV bundle cells. Sinoatrial node cells expressed POPDC2 abundantly, but expression of POPDC1 was sparse. Together, these results concur with predisposition to AV node disease in humans with loss-of-function variants in POPDC1 and POPDC2 and presence of sinus node disease in POPDC2, but not in POPDC1 related disease in human. Using population-level genetic data of more than 1 million individuals we showed that none of the familial variants were associated with clinical outcomes in heterozygous state, suggesting that heterozygous family members are unlikely to develop clinical manifestations and therefore might not necessitate clinical follow-up. Our findings provide evidence for POPDC2 as the cause of a novel Mendelian autosomal recessive cardiac syndrome, consistent with previous work showing that mice and zebrafish deficient in functional POPDC2 display sinus and AV node dysfunction.

• Download figure
• Open in new tab

Competing Interest Statement

Dr. Lorenzo Monserrat is a shareholder in Dilemma Solutions SL. Deanna Alexis Carere is an employee of GeneDx, LLC.

Funding Statement

We thank the families for their participation and collaboration. N.L. is supported by the Dutch Research Council (ZonMW VENI and Off-road). C.R.B., A.V.P. and N.L. acknowledge the support from the Dutch Heart Foundation (CVON 2018-30 PREDICT2 and CVON2014-18 CONCOR-GENES to C.R.B.) and the Netherlands Organization for Scientific Research (VICI fellowship, 016.150.610, to C.R.B.). This work was supported in part by the NIH awards R35GM128666 (M.V.A.) and T32GM092714 (F.Z.B.), a Sloan Research Fellowship (M.V.A.), and an American Heart Association Fellowship 23PRE1019634 (L.W.). This study makes use of data generated by the DECIPHER community. A full list of centres who contributed to the generation of the data is available from http://decipher.sanger.ac.uk and via email from decipher{at}sanger.ac.uk. Funding for the project was provided by the Wellcome Trust. Firth, H.V. et al (2009). DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans using Ensembl Resources. Website: https://www.deciphergenomics.org/. This project has been made possible in part by the Chan Zuckerberg Foundation (2019-202666) to M.N. and the British Heart Foundation and Deutsches Zentrum fur Herz-Kreislauf-Forschung (BHF/DZHK: SP/19/1/34461) to M.N. M.N. and L.M. were supported by the Rosetrees Trust Intermediate Project Grant (PGS23/100028) and NIHR Imperial BRC Cardiovascular Pilot Project Grant. L.M. was further supported by British Heart Foundation Clinical Research Training Fellowship (FS/CRTF/23/24444), British Society for Heart Failure Research Fellowship and Alexander Jansons Myocarditis UK. We thank Drs. Delphine Bichet and Florian Lesage (Universite de Nice Sophia Antipolis, France) for sharing the hTREK-1a plasmid. We thank Drs. Mohamed Hosny and Magdi Yacoub (Aswan Heart Centre, Magdi Yacoub Foundation, Egypt) for reviewing the phenotype of patients recruited at their center. We thank Sara Teichmann for sharing data on scRNA seq in human hearts.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study protocol was approved by the Amsterdam University Medical Center Research Ethics Committee and the local Institutional Review Boards of contributing centers. Signed informed consent was obtained from the patients or their parents.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes